31JUL

Astral raises GBP23m for cancer isotopes

2 min read

12:32UTC

Astral Systems, a Bristol deep-tech firm, raised GBP23m to make Actinium-225 and Lead-212, cancer-therapy isotopes now produced in only a handful of ageing reactors.

← Back to Humanoid hit $1.35bn on a customer order Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Astral's GBP23m round funds fusion-made cancer isotopes and shows how one large cheque can swing a UK region's total.

Astral Systems, a Bristol deep-tech firm, raised a GBP23m Series A to manufacture medical radioisotopes using its multi-state fusion reactors {{SRC:6}}. The isotopes, Actinium-225 and Lead-212, are used in targeted cancer therapy, and the world produces them in a handful of ageing reactors. Mercia Ventures, a UK regional venture capital firm, led the round, with Tees River, Daphni, Blast Club, Speedinvest and Playfair Capital joining.

Astral runs several small fusion reactions at once rather than chasing grid power from one large tokamak, and it uses those reactions to breed isotopes that decay too fast to stockpile. That method attacks a supply bottleneck, because current output depends on a few reactors built decades ago, any one of which going offline can strand a therapy. Deep-tech investors, not energy utilities, backed the round, since the product on sale is a scarce medical input rather than electricity.

A lab-to-market round of this size lands rarely, and when it does it moves a region's annual figure on its own. This is part of the South West's outsized 2025 swing, the kind of single large cheque that lifts a regional share one year and vanishes the next. Unlike CuspAI's foreign-only cap table, this round kept a UK lead, and it lands in the same Bristol cluster where mycelium-materials firm Mykor raised GBP4m earlier in the cycle .

Deep Analysis

In plain English

Astral Systems is a Bristol company building reactors that make medical radioisotopes, rare radioactive materials used to treat cancer. Two of them, Actinium-225 and Lead-212, can be attached to drugs that hunt down tumour cells and destroy them from the inside. These isotopes are made in only a few old nuclear reactors around the world, and there is nowhere near enough to go round. Astral uses a fusion reaction to breed them instead. The company raised £23m to build its production line at a former power station site in Gloucestershire, with the first isotopes expected to reach patients around early 2027.

Deep Analysis

Root Causes

The scarcity of Actinium-225 and Lead-212 comes from their production route. Both are bred in nuclear reactions and decay within days, so they cannot be stockpiled and must be made close to where they are used. Global supply currently leans on a small number of ageing reactors and legacy material stocks, so any outage strands the cancer therapies and trials that depend on them.

Astral's modular multi-state design runs several smaller fusion reactions in parallel as a manufacturing method for these isotopes, not as a bid for grid power. That is why five funds with little prior fusion exposure, including European seed specialists Daphni and Speedinvest, were willing to write cheques into a Series A: the product on sale is a scarce medical input with an identified shortage, rather than speculative electricity a decade away.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The medical isotope supply crises of 2009 and 2010, when the ageing NRU reactor in Canada and the Petten reactor in the Netherlands went offline for repairs at once, cutting the global supply of technetium-99m and forcing hospitals to ration scans. That fragility, with output concentrated in a few Cold War-era reactors, is exactly the bottleneck Astral aims to break by breeding isotopes on new hardware.

Counter-parallel: Actinium-225 has for years been produced in tiny quantities from decaying legacy thorium and uranium stocks at a handful of national laboratories, never enough to supply the clinical trials that need it. Accelerator-based production efforts have repeatedly been announced, but scaling them to clinical volumes has proved slow, a risk Astral's stated timeline to a first isotope in early 2027 must still clear.

Sources:UKTN

Mentions:Astral Systems →Daphni →IQ Capital →Bristol →Mykor →CuspAI →

First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026

Read original →

Causes and effects

This Event

Astral raises GBP23m for cancer isotopes

A single lab-to-market round of this scale can lift a region's annual funding share on its own, then vanish the next year.

Led to

Five seed rounds stir beneath megadeals

Astral Systems' £23m fusion round in June set the pattern of unglamorous sub-£15m sector-spread seed rounds this week's cluster continues.

Occurred 8 Jul 2026

Read story →

South West fund hits £157m, 283 firms

Astral Systems' £23m round is the single-cheque regional swing the South West Investment Fund's 283-business spread contrasts with.

Occurred 27 Jul 2026

Read story →

Different Perspectives

Fubon Financial

Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.

NATO Innovation Fund

The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.

Prime Movers Lab

Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.

Bosch and Schaeffler

Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.

UK founders raising seed through Series A

A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.